AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29433376
Drug: Placebo (lactose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (lactose pills, twice per day for one week)
Trial: 29253180
Drug: Active music
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active music therapy intervention
Trial: 29253180
Drug: Passive music
RxNorm normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive music therapy intervention
Trial: 10201458
Drug: Dicyclomine (Dic)
DrugBank: Dicyclomine (DB00804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dicyclomine (Dic) 20 mg four times daily
Trial: 9395592
Drug: HIV antibody
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV antibody testing, counseling and education programme
Trial: 30717942
Drug: Psychosocial intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychosocial intervention programme (six 90-min educational sessions, held weekly)
Trial: 26911582
Drug: Intravenous exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous exenatide for up to 72 hours
Trial: 31251546
Drug: Tazarotene 0.1%
RxNorm normalized name: TAZAROTENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazarotene 0.1% cream
Trial: 10069275
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of sufentanil (3.6 microg/kg/h) and midazolam (0.08 mg/kg/h)
Trial: 10069275
Drug: Bolus administration
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus administration of sufentanil (2 microg/kg) and midazolam (0.03 mg/kg)
Trial: 10069275
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of sufentanil and midazolam
Trial: 10069275
Drug: Bolus administration
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus administration
Trial: 8179132
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion
Trial: 10069275
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion and bolus administration
Trial: 2033418
Drug: Surgery plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery plus conventional chemotherapy (POG 8441)
Trial: 11475180
Drug: Group F
RxNorm normalized name: Prostaglandin group F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group F + P + S (1.0 microgram/kg fentanyl and 0.5 mg/kg propofol prior to induction)
Trial: 8052871
Drug: Etoposide 200
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide 200 mg/m2 days 1 through 3 and vincristine 1.4 mg/m2 days 1 and 8 (EV)
Trial: 478206
Drug: Domperidone (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (two 10‐mg tablets t.i.d. before meals)
Trial: 25530265
Drug: Micafungin 300
RxNorm normalized name: Micafungin
DrugBank: Micafungin (DB01141)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Micafungin 300 mg day(‐1) intravenous monotherapy
Trial: 25530265
Drug: Control monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control monotherapy (lipid amphotericin B 5 mg kg(‐1) day(‐1), voriconazole 8 mg kg(‐1) day(‐1), or caspofungin 50 mg day(‐1))
Trial: 3393382
Drug: Salbutamol (0.12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (0.12 mg/kg) administered 300 minutes before exercise test
Trial: 3393382
Drug: Clenbuterol (0.001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clenbuterol (0.001 mg/kg) administered 300 minutes before exercise test
Trial: 29096833
Drug: Atorvastatin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin monotherapy (Control)
Trial: 21668938
Drug: C6 injection
RxNorm normalized name: HYDROGENATED C6-20 POLYOLEFIN (100 CST)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C6 injection
Trial: 21668938
Drug: C5 injection
RxNorm normalized name: dipentaerythrityl hexa C5-10 acid esters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C5 injection
Trial: 9331308
Drug: Home intravenous
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home intravenous (IV) hydration after tonsillectomy
Trial: 31983371
Drug: Active tDCS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active tDCS (2 mA, 20 min) combined with speech-language therapy
Trial: 31983371
Drug: Sham tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham tDCS combined with speech-language therapy
Trial: 27524671
Drug: Training group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training group with weekly bisphosphonate regimen
Trial: 27524671
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with weekly bisphosphonate regimen
Trial: 20816546
Drug: Oxygen delivered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen delivered via nasal cannula at 2 L per min for 7 days
Trial: 20816546
Drug: Room air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room air delivered via nasal cannula at 2 L per min for 7 days
Trial: 15922813
Drug: Stable dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable dosing of salmeterol/fluticasone propionate (SAL/FP) 50/250 microg BID
Trial: 15922813
Drug: Adjustable maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjustable maintenance dosing of formoterol/budesonide (FOR/BUD) 6/200 microg BID
Trial: 15922813
Drug: Stable dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable dosing of SAL/FP
Trial: 15922813
Drug: Adjustable maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjustable maintenance dosing of FOR/BUD
Trial: 12890374
Drug: Heliox-driven beta(2)-agonist
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heliox-driven beta(2)-agonist therapy (Berotec)
Trial: 8886564
Drug: HOMA model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HOMA model assessment of insulin resistance (IR) and insulin secretion from fasting glucose and insulin concentrations.
Trial: 8886564
Drug: HOMA model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HOMA model assessment of insulin secretion.
Trial: 1886349
Drug: Naftidrofuryl (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftidrofuryl (2 x 200 mg/day)
Trial: 6682324
Drug: Carteolol 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carteolol 15 mg/day
Trial: 31060979
Drug: Guadecitabine 60
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Guadecitabine 60 mg/m2
Trial: 31060979
Drug: Guadecitabine 90
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Guadecitabine 90 mg/m2
Trial: 31060979
Drug: Guadecitabine 60
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Guadecitabine 60 mg/m2 and 90 mg/m2
Trial: 26502953
Drug: Control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition (no treatment)
Trial: 17437473
Drug: 0.1 mL
RxNorm normalized name: ethanol 0.1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mL intradermally at two sites on one day
Trial: 4846329
Drug: Centrally stimulant
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Centrally stimulant and depressant drugs
Trial: 30689494
Drug: Untailored intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Untailored intervention (iPad-based Vaccine Information Sheet)
Trial: 29072001
Drug: Eye-acupuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye-acupuncture therapy
Trial: 18438851
Drug: Step-up therapy
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Step-up therapy
Trial: 18438851
Drug: Parallel triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parallel triple therapy
Trial: 9217034
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and hormone therapy
Trial: 3302112
Drug: Cinnarizine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnarizine (75 mg bd)
Trial: 31128568
Drug: Intranasal vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal vasopressin
Trial: 22972879
Drug: Cystine (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cystine (700 mg) and theanine (280 mg) administered for 10 days (4 days before to 5 days after surgery)
Trial: 20601414
Drug: Cefuroxime (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime (1.5 g intravenous)
Trial: 18211575
Drug: Topical wound
RxNorm normalized name: Solox Gel Silver Antimicrobial Topical Wound Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical wound treatments
Trial: 14563183
Drug: Methotrexate (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (i.v. 25 mg/week for 3 months, then oral 25 mg/week for 3 months)
Trial: 14563183
Drug: Azathioprine (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (oral 2 mg/kg per day for 6 months)
Trial: 8720610
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg acipimox
Trial: 2944997
Drug: Zomepirac 100
RxNorm normalized name: zomepirac 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zomepirac 100 mg
Trial: 7586360
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (uncoated circuits with full heparin dose; n = 17)
Trial: 8994317
Drug: TBE-vaccine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBE-vaccine (0.4 microgram)
Trial: 8994317
Drug: TBE-vaccine (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBE-vaccine (0.75 microgram)
Trial: 8994317
Drug: TBE-vaccine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBE-vaccine (1.5 micrograms)
Trial: 1479106
Drug: Calcipotriol ointment
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol ointment (50 micrograms/gm) twice daily for 4 weeks
Trial: 7924241
Drug: Group Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Therapy (GT)
Trial: 29905824
Drug: 4.4 g
RxNorm normalized name: ALUMINUM CHLOROHYDRATE 4.4 g in 1 mg BUCCAL EMULSION [Antiperspirant]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.4 g milk protein + 4.4 g rice protein/d
Trial: 24568963
Drug: Low-dose clonidine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose clonidine
Trial: 20148772
Drug: Entropy-guided sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entropy-guided sevoflurane administration
Trial: 20148772
Drug: Standard practice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard practice sevoflurane administration
Trial: 19402358
Drug: PMT-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PMT-based treatment
Trial: 12355675
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of psychotherapy and medications
Trial: 10514397
Drug: Topical estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical estrogen patch
Trial: 1742002
Drug: Adjusted-dose heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted-dose heparin
Trial: 30280443
Drug: Parental drug
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parental drug use
Trial: 26387692
Drug: Modified protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified protocol (2 mg per kg body weight given in a single infusion over 2 h, repeated every 4 months)
Trial: 26387692
Drug: Standard protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard protocol (1 mg per kg body weight over 4 h on 3 successive days, repeated every 4 months)
Trial: 18571082
Drug: Data-injection ring
RxNorm normalized name: NO DATA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Data-injection ring system
Trial: 18571082
Drug: No data-injection
RxNorm normalized name: NO DATA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No data-injection system
Trial: 16025732
Drug: Direct hypnotic
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct hypnotic procedure using the Harvard Group Scale of Hypnotic Susceptibility: Form A (HGSHS:A)
Trial: 16025732
Drug: Indirect hypnotic
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indirect hypnotic procedure using the Alman‐Wexler Indirect Hypnotic Susceptibility Scale (AWIHSS)
Trial: 12064813
Drug: Norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin 400 mg/day
Trial: 10495686
Drug: Metoprolol administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol administration at an initial dose of 25 mg/day (12.5 mg for class III-IV patients), increased to a maximum of 200 mg/day
Trial: 1773685
Drug: Decision support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decision support system for insulin-dose adjustment
Trial: 21284343
Drug: Medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose of arginine (12.3 g per day)
Trial: 25855918
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of arginine (18.9 g per day)
Trial: 24622416
Drug: 6.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.5 mg/kg ATG over four days
Trial: 24622416
Drug: 6.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.5 mg/kg ATG
Trial: 18661120
Drug: eMPC advised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eMPC advised insulin infusion
Trial: 15202162
Drug: Granisetron (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (single oral dose)
Trial: 15202162
Drug: Ondansetron (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (2 intravenous doses of 0.15 mg/kg followed by 1 oral dose)
Trial: 2813482
Drug: Cocaine infusion
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine infusion
Trial: 2563317
Drug: Pancuronium 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium 0.15 mg.kg‐1
Trial: 26747037
Drug: Daily smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily smoking
Trial: 16606815
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen (0.625 mg/d)
Trial: 19467365
Drug: Ingenol mebutate
RxNorm normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ingenol mebutate gel 0.05% for 2 or 3 days
Trial: 19467365
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle gel for 3 days
Trial: 16323095
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg daily for 7-14 days)
Trial: 16323095
Drug: Levofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (500 mg daily for 7-14 days)
Trial: 9008458
Drug: Verapamil 240
RxNorm normalized name: verapamil 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 240 mg
Trial: 10190078
Drug: Intensive course
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive course of high fractional X‐ray therapy (cumulative dose up to 25 Gy) with direct protracted endolymphatic chemotherapy with 5‐fluorouracil (5‐FU) instilled in 600 mg/m2 each day before operation, up to a cumulative dose of 5 g.
Trial: 10190078
Drug: Ukrain as
RxNorm normalized name: Ukrain cation
DrugBank: Ukrain cation (DB17150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ukrain as monotherapy, 10 mg each second day before operation (up to a cumulative dose of 60 mg) and a total of 40 mg after surgical intervention, with repeated courses (100 mg/per course) 6 months after surgical operation.
Trial: 8298540
Drug: Exploratory therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exploratory therapy
Trial: 2245269
Drug: Prescriptive therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescriptive therapy
Trial: 15507176
Drug: Trastuzumab added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab added to chemotherapy
Trial: 28532387
Drug: Prediction model
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prediction model with 4 clinical covariates, 98 biomarkers, and 24 biomarker-by-treatment interactions
Trial: 26380442
Drug: Jiangyabao serial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jiangyabao serial drugs combined with Western medicine (WM)
Trial: 26380442
Drug: Simulative agents
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simulative agents of Jiangyabao serial drugs combined with Western medicine (WM)
Trial: 26380442
Drug: Combined hypotensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined hypotensive treatment program with Nifedipine Sustained Release Tablet and Hydrochlorothiazide
Trial: 20333384
Drug: HA-Irinotecan (HA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA-Irinotecan (HA 1,000 mg/m(2) and irinotecan at 350 mg/m(2))
Trial: 20333384
Drug: irinotecan (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: irinotecan (350 mg/m(2))
Trial: 12508081
Drug: Triiodothyronine (T3)
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triiodothyronine (T3) and hydrocortisone supplementation (6 micro g.kg(‐1).d(‐1) of T3 with 1 mg.kg(‐1).d(‐1) of hydrocortisone)
Trial: 10335931
Drug: Ciprofloxacin 750
RxNorm normalized name: ciprofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 750 mg p.o. twice a day
Trial: 8915757
Drug: Systemic rIL-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic rIL-2 infusion following intrathecal treatment
Trial: 8915757
Drug: Clinical condition
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical condition post-treatment
Trial: 387070
Drug: Co-trimoxazole (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (800 mg sulphamethoxazole and 160 mg trimethoprim) administered as a single 10 ml intravenous infusion during surgery.
Trial: 387070
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as a single 10 ml intravenous infusion during surgery.
Trial: 28864487
Drug: Pap screening
RxNorm normalized name: acetaminophen / hydrocodone bitartrate Oral Capsule [Hyco-pap]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pap screening (HCP-administered)
Trial: 2896826
Drug: Two-component vaccine
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-component vaccine containing formaldehyde detoxified lymphocytosis promoting factor (LPF) and filamentous haemagglutinin
Trial: 2896826
Drug: Placebo (vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vaccine solvent)
Trial: 28835228
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (100,000 International Units cholecalciferol monthly)
Trial: 25462419
Drug: Twice-daily HF-rTMS
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily HF-rTMS (10 Hz) over the left dorsolateral prefrontal cortex for 2 weeks (60,000 pulses)
Trial: 23619819
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg meloxicam tablet
Trial: 23619819
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg meloxicam suspension
Trial: 21073813
Drug: Intercept oral
RxNorm normalized name: INTERCEPTOR Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intercept oral specimen collection device